Tumor cell recognition and cytotoxicity pathways

Tumor cell recognition and cytotoxicity pathways refer to the integrated biological processes through which the immune system identifies and eliminates neoplastic cells. This system relies on the interaction between immune effector cells, such as CD8+ T lymphocytes and Natural Killer (NK) cells, and target tumor cells via specific receptor-ligand pairings like the T-cell receptor (TCR) and MHC-peptide complexes [PMID: 24068445]. Upon successful recognition, effector cells trigger cytotoxicity through the release of lytic granules containing perforin and granzymes or by engaging death receptors such as FAS (CD95) to induce apoptosis [PMID: 11418641]. Cancer cells often evolve to evade these pathways by downregulating antigen presentation machinery or exploiting inhibitory checkpoints like the PD-1/PD-L1 axis [PMID: 28351932]. Therapeutic strategies targeting these pathways include immune checkpoint inhibitors, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapies, which aim to restore or bypass natural recognition mechanisms [PMID: 30531909]. Consequently, these pathways are central to the field of cancer immunotherapy and represent a broad framework for drug development rather than a single molecular target.

Other names

Tumor immunosurveillanceImmune-mediated cytotoxicityNK cell-mediated cytotoxicityT-cell mediated cytotoxicity

Enhancement of immune cell-mediated tumor recognition and induction of effector-cell-mediated apoptosis via checkpoint inhibition, direct engagement of T-cells, or adoptive transfer of engineered immune cells.